查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1467641

2024-2032 年按药物类别、给药途径、最终用户和地区分類的肺动脉高血压药物市场报告

Pulmonary Arterial Hypertension Drugs Market Report by Drug Class, Route of Administration, End User, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 146 Pages | 商品交期: 2-3个工作天内

价格

2023年全球肺动脉高压（PAH）药物IMARC Group规模达77亿美元。

肺动脉高压（PAH）是一种危及生命的疾病，其特征是连接心臟和肺部的动脉血压升高。它会导致动脉壁收紧和变窄，从而对心臟施加额外的压力以泵血并削弱肌肉。在不利的情况下，它还会损害心臟泵血的能力，最终导致心臟衰竭。 PAH 的特征是呼吸急促、疲劳以及脚踝和腿部肿胀。它可以透过各种测试来诊断，例如超音波心动图、电脑断层扫描 (CT) 扫描、胸部 X 光检查和通气灌注扫描。通常使用多种药物治疗，例如内皮素受体拮抗剂（ERA）、血管扩张剂、钙通道阻断剂（CCB）、抗凝血剂、利尿剂和强心配醣体。这些药物可以吸入、注射或口服。

心血管和肺部疾病盛行率的增加是推动市场成长的关键因素之一。此外，越来越多的老年人口更容易患此类疾病，这也推动了市场的成长。与此一致的是，生活方式的改变，如过量饮酒、缺乏体力活动和不健康的饮食模式，增加了高血压的风险。再加上新型孤儿药和技术先进的 PAH 治疗设备的开发，有利于市场成长。其他因素，包括大众对 PAH 可用治疗替代方案的认识的提高，以及全球医疗基础设施的改善，预计将进一步推动市场。

本报告回答的关键问题

  • 2023年全球肺动脉高压（PAH）药物市场规模？
  • 2024-2032年全球肺动脉高压（PAH）药物市场的预期成长率为何？
  • 推动全球肺动脉高压（PAH）药物市场的关键因素是什么？
  • COVID-19 对全球肺动脉高压 (PAH) 药物市场有何影响？
  • 根据药物类别，全球肺动脉高压 (PAH) 药物市场的细分如何？
  • 根据给药途径，全球肺动脉高压（PAH）药物市场的细分如何？
  • 全球肺动脉高压（PAH）药物市场的关键区域有哪些？
  • 谁是全球肺动脉高压（PAH）药物市场的主要参与者/公司？

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 资料来源
    • 主要资源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球肺动脉高压 (PAH) 药物市场

  • 市场概况
  • 市场业绩
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：依药物类别

  • 内皮素受体拮抗剂 (ERA)
    • 市场走向
    • 市场预测
  • 血管扩张剂
    • 市场走向
    • 市场预测
  • 磷酸二酯酶 5 (PDE-5) 抑制剂
    • 市场走向
    • 市场预测
  • 可溶性鸟苷酸环化酶 (sGC) 刺激剂
    • 市场走向
    • 市场预测
  • 钙通道阻断剂 (CCB)
    • 市场走向
    • 市场预测
  • 前列环素和前列环素类似物
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 7 章：市场区隔：依管理途径

  • 吸入
    • 市场走向
    • 市场预测
  • 可注射
    • 市场走向
    • 市场预测
  • 口服给药
    • 市场走向
    • 市场预测

第 8 章：市场区隔：依最终用户

  • 医院
    • 市场走向
    • 市场预测
  • 诊所
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 9 章：市场区隔：按地区

  • 北美洲
    • 美国
      • 市场走向
      • 市场预测
    • 加拿大
      • 市场走向
      • 市场预测
  • 亚太地区
    • 中国
      • 市场走向
      • 市场预测
    • 日本
      • 市场走向
      • 市场预测
    • 印度
      • 市场走向
      • 市场预测
    • 韩国
      • 市场走向
      • 市场预测
    • 澳洲
      • 市场走向
      • 市场预测
    • 印尼
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 欧洲
    • 德国
      • 市场走向
      • 市场预测
    • 法国
      • 市场走向
      • 市场预测
    • 英国
      • 市场走向
      • 市场预测
    • 义大利
      • 市场走向
      • 市场预测
    • 西班牙
      • 市场走向
      • 市场预测
    • 俄罗斯
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 拉丁美洲
    • 巴西
      • 市场走向
      • 市场预测
    • 墨西哥
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 中东和非洲
    • 市场走向
    • 市场细分：按国家/地区
    • 市场预测

第 10 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 11 章：价值链分析

第 12 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 13 章：价格分析

第14章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Actelion Pharmaceuticals Ltd (Johnson & Johnson)
    • Arena Pharmaceuticals Inc.
    • AstraZeneca PLC
    • Bayer Aktiengesellschaft
    • Daiichi Sankyo Company Limited
    • Gilead Science Inc.
    • GlaxoSmithKline PLC
    • Merck KGaA
    • Novartis International AG
    • Pfizer Inc.
    • United Therapeutics Corporation
Product Code: SR112024A2399

The global pulmonary arterial hypertension (PAH) drugs market size reached US$ 7.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 11.6 Billion by 2032, exhibiting a growth rate (CAGR) of 4.6% during 2024-2032.

Pulmonary arterial hypertension (PAH) refers to a life-threatening medical condition characterized by high blood pressure in the arteries that connect the heart to the lungs. It causes the artery walls to tighten and narrow down, thereby exerting additional pressure on the heart to pump blood and weakening the muscles. In adverse cases, it can also compromise the heart's capacity to pump blood, thus eventually causing heart failure. PAH is characterized by shortness of breath, fatigue and swelling in ankles and legs. It is diagnosed through various tests, such as an echocardiogram, computer tomography (CT) scans, chest X-rays and ventilation-perfusion scans. It is usually treated using various drugs, such as endothelin receptor antagonists (ERAs), vasodilators, calcium channel blockers (CCBs), anticoagulants, diuretics and cardiac glycosides. These drugs can be inhaled, injected or orally administered.

The increasing prevalence of cardiovascular and pulmonary disorders is one of the key factors driving the growth of the market. Furthermore, the rising geriatric population that is more susceptible to such medical ailments is providing a boost to the market growth. In line with this, changes in lifestyles, such as excessive alcohol consumption, a lack of physical activity, and unhealthy dietary patterns, have enhanced the risks of hypertension and high blood pressure. This, along with the development of novel orphan drugs and technologically advanced devices for the treatment of PAH, is favoring the market growth. Other factors, including increasing awareness among the masses regarding the available treatment alternatives for PAH, and improving healthcare infrastructure across the globe, are expected to drive the market further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global pulmonary arterial hypertension (PAH) drugs market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on drug class, route of administration and end user.

Breakup by Drug Class:

Endothelin Receptor Antagonists (ERAs)

Vasodilators

Phosphodiesterase-5 (PDE-5) Inhibitors

Soluble Guanylate Cyclase (sGC) Stimulators

Calcium Channel Blockers (CCBs)

Prostacyclin and Prostacyclin Analogs

Others

Breakup by Route of Administration:

Inhalation

Injectable

Oral Administration

Breakup by End User:

Hospitals

Clinics

Others

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Actelion Pharmaceuticals Ltd (Johnson & Johnson), Arena Pharmaceuticals Inc., AstraZeneca PLC, Bayer Aktiengesellschaft, Daiichi Sankyo Company Limited, Gilead Science Inc., GlaxoSmithKline PLC, Merck KGaA, Novartis International AG, Pfizer Inc. and United Therapeutics Corporation.

Key Questions Answered in This Report

  • 1. What was the size of the global Pulmonary Arterial Hypertension (PAH) drugs market in 2023?
  • 2. What is the expected growth rate of the global Pulmonary Arterial Hypertension (PAH) drugs market during 2024-2032?
  • 3. What are the key factors driving the global Pulmonary Arterial Hypertension (PAH) drugs market?
  • 4. What has been the impact of COVID-19 on the global Pulmonary Arterial Hypertension (PAH) drugs market?
  • 5. What is the breakup of the global Pulmonary Arterial Hypertension (PAH) drugs market based on the drug class?
  • 6. What is the breakup of the global Pulmonary Arterial Hypertension (PAH) drugs market based on the route of administration?
  • 7. What are the key regions in the global Pulmonary Arterial Hypertension (PAH) drugs market?
  • 8. Who are the key players/companies in the global Pulmonary Arterial Hypertension (PAH) drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Pulmonary Arterial Hypertension (PAH) Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 Endothelin Receptor Antagonists (ERAs)
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Vasodilators
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Phosphodiesterase-5 (PDE-5) Inhibitors
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Soluble Guanylate Cyclase (sGC) Stimulators
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Calcium Channel Blockers (CCBs)
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Prostacyclin and Prostacyclin Analogs
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Others
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast

7 Market Breakup by Route of Administration

  • 7.1 Inhalation
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Injectable
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Oral Administration
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Clinics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Actelion Pharmaceuticals Ltd (Johnson & Johnson)
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
    • 14.3.2 Arena Pharmaceuticals Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 AstraZeneca PLC
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Bayer Aktiengesellschaft
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Daiichi Sankyo Company Limited
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Gilead Science Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 GlaxoSmithKline PLC
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Merck KGaA
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Novartis International AG
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
    • 14.3.10 Pfizer Inc.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 United Therapeutics Corporation
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Pulmonary Arterial Hypertension Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Pulmonary Arterial Hypertension Drugs Market: Breakup by Drug Class (in %), 2023
  • Figure 4: Global: Pulmonary Arterial Hypertension Drugs Market: Breakup by Route of Administration (in %), 2023
  • Figure 5: Global: Pulmonary Arterial Hypertension Drugs Market: Breakup by End User (in %), 2023
  • Figure 6: Global: Pulmonary Arterial Hypertension Drugs Market: Breakup by Region (in %), 2023
  • Figure 7: Global: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 8: Global: Pulmonary Arterial Hypertension Drugs (Endothelin Receptor Antagonists - ERAs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Pulmonary Arterial Hypertension Drugs (Endothelin Receptor Antagonists - ERAs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Pulmonary Arterial Hypertension Drugs (Vasodilators) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Pulmonary Arterial Hypertension Drugs (Vasodilators) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Pulmonary Arterial Hypertension Drugs (Phosphodiesterase-5 - PDE-5 Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Pulmonary Arterial Hypertension Drugs (Phosphodiesterase-5 - PDE-5 Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Pulmonary Arterial Hypertension Drugs (Soluble Guanylate Cyclase- sGC Stimulators) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Pulmonary Arterial Hypertension Drugs (Soluble Guanylate Cyclase- sGC Stimulators) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Pulmonary Arterial Hypertension Drugs (Calcium Channel Blockers - CCBs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Pulmonary Arterial Hypertension Drugs (Calcium Channel Blockers - CCBs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Pulmonary Arterial Hypertension Drugs (Prostacyclin and Prostacyclin Analogs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Pulmonary Arterial Hypertension Drugs (Prostacyclin and Prostacyclin Analogs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Pulmonary Arterial Hypertension Drugs (Other Drug Classes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Pulmonary Arterial Hypertension Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Pulmonary Arterial Hypertension Drugs (Inhalation) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Pulmonary Arterial Hypertension Drugs (Inhalation) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Pulmonary Arterial Hypertension Drugs (Injectable) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Pulmonary Arterial Hypertension Drugs (Injectable) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Pulmonary Arterial Hypertension Drugs (Oral Administration) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Pulmonary Arterial Hypertension Drugs (Oral Administration) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Pulmonary Arterial Hypertension Drugs (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Pulmonary Arterial Hypertension Drugs (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Global: Pulmonary Arterial Hypertension Drugs (Clinics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Global: Pulmonary Arterial Hypertension Drugs (Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Global: Pulmonary Arterial Hypertension Drugs (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Global: Pulmonary Arterial Hypertension Drugs (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: North America: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: North America: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: United States: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: United States: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Canada: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Canada: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: Asia Pacific: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: Asia Pacific: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: China: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: China: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Japan: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Japan: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: India: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: India: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: South Korea: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: South Korea: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Australia: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Australia: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Indonesia: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Indonesia: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Others: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Others: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Europe: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Europe: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Germany: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Germany: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: France: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: France: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: United Kingdom: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: United Kingdom: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Italy: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Italy: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Spain: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Spain: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Russia: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Russia: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Others: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Others: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Latin America: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Latin America: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Brazil: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Brazil: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Mexico: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: Mexico: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 78: Others: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 79: Others: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 80: Middle East and Africa: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 81: Middle East and Africa: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 82: Global: Pulmonary Arterial Hypertension Drugs Industry: SWOT Analysis
  • Figure 83: Global: Pulmonary Arterial Hypertension Drugs Industry: Value Chain Analysis
  • Figure 84: Global: Pulmonary Arterial Hypertension Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Pulmonary Arterial Hypertension Drugs Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Pulmonary Arterial Hypertension Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2024-2032
  • Table 3: Global: Pulmonary Arterial Hypertension Drugs Market Forecast: Breakup by Route of Administration (in Million US$), 2024-2032
  • Table 4: Global: Pulmonary Arterial Hypertension Drugs Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 5: Global: Pulmonary Arterial Hypertension Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Pulmonary Arterial Hypertension Drugs Market Structure
  • Table 7: Global: Pulmonary Arterial Hypertension Drugs Market: Key Players